Hanwha Q Cells Co. Ltd. (NASDAQ:HQCL)‘s stock had its “neutral” rating reaffirmed by research analysts at Roth Capital in a report released on Monday. They currently have a $10.00 price objective on the stock, down from their prior price objective of $13.00. Roth Capital’s price target suggests a potential upside of 13.25% from the company’s previous close.
Separately, Zacks Investment Research cut Hanwha Q Cells Co. from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 9th.
Shares of Hanwha Q Cells Co. (NASDAQ:HQCL) traded down 6.09% during midday trading on Monday, reaching $8.79. The company’s stock had a trading volume of 35,256 shares. Hanwha Q Cells Co. has a one year low of $8.74 and a one year high of $9.45. The stock’s 50-day moving average is $0.00 and its 200-day moving average is $0.00.
Hanwha Q Cells Co. (NASDAQ:HQCL) last announced its earnings results on Tuesday, November 22nd. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.29. Hanwha Q Cells Co. had a return on equity of 42.02% and a net margin of 6.73%. The business earned $707.80 million during the quarter, compared to analysts’ expectations of $653.40 million. The company’s revenue was up 65.7% compared to the same quarter last year. On average, analysts expect that Hanwha Q Cells Co. will post $1.67 EPS for the current year.
Several large investors have recently bought and sold shares of the stock. Guggenheim Capital LLC raised its stake in Hanwha Q Cells Co. by 27.8% in the second quarter. Guggenheim Capital LLC now owns 493,596 shares of the company’s stock worth $7,108,000 after buying an additional 107,408 shares during the period. Morgan Stanley raised its stake in Hanwha Q Cells Co. by 12.8% in the third quarter. Morgan Stanley now owns 181,537 shares of the company’s stock worth $2,035,000 after buying an additional 20,545 shares during the period. Barclays PLC bought a new stake in Hanwha Q Cells Co. during the first quarter worth about $432,000. Oxford Asset Management bought a new stake in Hanwha Q Cells Co. during the second quarter worth about $392,000. Finally, KBC Group NV raised its stake in Hanwha Q Cells Co. by 36.3% in the third quarter. KBC Group NV now owns 17,098 shares of the company’s stock worth $192,000 after buying an additional 4,554 shares during the period. Institutional investors and hedge funds own 1.29% of the company’s stock.
About Hanwha Q Cells Co.